Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 18/20 | 0.80 |
| ▸ | EPHB4 | P54760 | 12/20 | 0.80 |
| ▸ | ERBB2 | P04626 | 5/20 | 0.80 |
| ▸ | EGFR | P00533 | 5/20 | 0.80 |
| ▸ | CLK1 | P49759 | 2/20 | 0.80 |
| ▸ | AURKA | O14965 | 1/20 | 0.80 |
| ▸ | INSR | P06213 | 1/20 | 0.80 |
| ▸ | FBP1 | P09467 | 1/20 | 0.80 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.80 |
| ▸ | FLT4 | P35916 | 1/20 | 0.80 |
| ▸ | TEK | Q02763 | 1/20 | 0.80 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.80 |
| ▸ | RET | P07949 | 1/20 | 0.80 |
| ▸ | KIF5B | P33176 | 1/20 | 0.80 |
| ▸ | EPHA2 | P29317 | 14/20 | 0.78 |
| ▸ | FLT1 | P17948 | 3/20 | 0.76 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.76 |
| ▸ | LCK | P06239 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22590721 | 0.92 | EGFR (0.80) | KDREPHB4ERBB2EGFRCLK1 | |
| SCHEMBL22630825 | 0.90 | KDR (0.77) | KDREPHB4ERBB2EGFRCLK1 | |
| SCHEMBL907182 | 0.90 | KDR (0.77) | KDREPHB4ERBB2EGFRCLK1 | |
| SCHEMBL22630824 | 0.90 | KDR (0.69) | KDREPHB4ERBB2EGFRCLK1 | |
| SCHEMBL907124 | 0.90 | KDR (0.72) | KDREPHB4ERBB2EGFRCLK1 | |
| SCHEMBL907447 | 0.89 | KDR (0.70) | KDREPHB4ERBB2EGFRCLK1 | |
| Hydrochloric Acid SCHEMBL907176 | 0.89 | KDR (0.71) | KDREPHB4ERBB2EGFRCLK1 | |
| SCHEMBL2099106 | 0.89 | EGFR (1.00) | KDREPHB4ERBB2EGFRCLK1 | |
| SCHEMBL5864546 | 0.89 | KDR (0.82) | KDREPHB4ERBB2EGFRCLK1 | |
| SCHEMBL14095961 | 0.89 | EGFR (0.80) | KDREPHB4ERBB2EGFRCLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0566226-B1 | Quinazoline derivatives | ZENECA LTD (GB) | 1995-11-08 | — | — | EP | claimed |
| US-5457105-A | anticancer use; e.g. 4-(3'-chloro-4'-fluoroanilino)-6,7-dimethoxyquinazoline (gefitinib) | ZENECA LIMITED (GB) | 1995-10-10 | — | — | US | claimed |
| EP-0566226-A1 | Quinazoline derivatives | ZENECA LIMITED (GB) | 1993-10-20 | — | — | EP | claimed |
| US-20160303127-A1 | COMBINATION THERAPY WITH C-MET AND EGFR ANTAGONISTS | GENENTECH INC (US) | 2016-10-20 | — | — | US | disclosed |
| US-20150086545-A1 | COMBINATION THERAPY OF HER EXPRESSING TUMORS | GENENTECH, INC. (US) | 2015-03-26 | — | — | US | disclosed |
| US-20150056207-A1 | COMBINATION THERAPY WITH C-MET AND EGFR ANTAGONISTS | GENENTECH INC (US) | 2015-02-26 | — | — | US | disclosed |
| US-20120251530-A1 | COMBINATION THERAPY OF HER EXPRESSING TUMORS | SLIWKOWSKI MARK X (US) | 2012-10-04 | — | — | US | disclosed |
| US-20120189573-A1 | Methods of using death receptor agonists and EGFR inhibitors | GENENTECH, INC. (US) | 2012-07-26 | — | — | US | disclosed |
| US-8163287-B2 | Combination therapy of her expressing tumors | GENENTECH, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-20110262436-A1 | TREATMENT METHOD | GENENTECH, INC. (US) | 2011-10-27 | — | — | US | disclosed |
| EP-2257293-A2 | COMBINATION THERAPY WITH C-MET AND EGFR ANTAGONISTS | Genentech, Inc. (US) | 2010-12-08 | — | — | EP | disclosed |
| US-20090155247-A1 | Methods of Using Death Receptor Agonists and EGFR Inhibitors | ASHKENAZI AVI J | 2009-06-18 | — | — | US | disclosed |
| US-20080199480-A1 | Methods for Identifying Risk of Type II Diabetes and Treatments Thereof | SEQUENOM, INC. (US) | 2008-08-21 | — | — | US | disclosed |
| US-20080199480-A1 | Methods for Identifying Risk of Type II Diabetes and Treatments Thereof | SEQUENOM, INC. (US) | 2008-08-21 | — | — | US | disclosed |
| US-20070020261-A1 | Combination therapy of her expressing tumors | GENENTECH, INC. | 2007-01-25 | — | — | US | disclosed |
| US-20060188498-A1 | Methods of using death receptor agonists and EGFR inhibitors | GENENTECH, INC. | 2006-08-24 | — | — | US | disclosed |
| US-5616582-A | Use as anticancer agents; e.g. gefitinib | ZENECA LIMITED (GB) | 1997-04-01 | — | — | US | disclosed |
| EP-0566226-B1 | Quinazoline derivatives | ZENECA LTD (GB) | 1995-11-08 | — | — | EP | disclosed |
| US-5457105-A | anticancer use; e.g. 4-(3'-chloro-4'-fluoroanilino)-6,7-dimethoxyquinazoline (gefitinib) | ZENECA LIMITED (GB) | 1995-10-10 | — | — | US | disclosed |
| EP-0566226-A1 | Quinazoline derivatives | ZENECA LIMITED (GB) | 1993-10-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120189573-A1 | Methods of using death receptor agonists and EGFR inhibitors | EGFR, ERBB4, TNFRSF9 | KDR 50/4885EPHB4 40/4885ERBB2 7/4885 |
| US-20090155247-A1 | Methods of Using Death Receptor Agonists and EGFR Inhibitors | EGFR, ERBB4, TNFRSF9 | KDR 50/4885EPHB4 40/4885ERBB2 7/4885 |
| US-20150086545-A1 | COMBINATION THERAPY OF HER EXPRESSING TUMORS | ERBB2, EGFR, ERBB3 | KDR 34/4885EPHB4 466/4885ERBB2 1/4885 |
| US-20080199480-A1 | Methods for Identifying Risk of Type II Diabetes and Treatments Thereof | SLC5A2, GCKR, IAPP | KDR 2859/4885EPHB4 1038/4885ERBB2 2284/4885 |
| US-20060188498-A1 | Methods of using death receptor agonists and EGFR inhibitors | EGFR, ERBB4, TNFRSF9 | KDR 50/4885EPHB4 40/4885ERBB2 7/4885 |
| US-20070020261-A1 | Combination therapy of her expressing tumors | ERBB2, EGFR, ERBB3 | KDR 34/4885EPHB4 466/4885ERBB2 1/4885 |
| US-20160303127-A1 | COMBINATION THERAPY WITH C-MET AND EGFR ANTAGONISTS | MET, EGFR, ERBB2 | KDR 33/4885EPHB4 109/4885ERBB2 3/4885 |
| US-20110262436-A1 | TREATMENT METHOD | HGF, HDGF, FGF2 | KDR 424/4885EPHB4 1329/4885ERBB2 26/4885 |
| US-20150056207-A1 | COMBINATION THERAPY WITH C-MET AND EGFR ANTAGONISTS | MET, EGFR, ERBB2 | KDR 33/4885EPHB4 109/4885ERBB2 3/4885 |
| US-20120251530-A1 | COMBINATION THERAPY OF HER EXPRESSING TUMORS | ERBB2, EGFR, ERBB3 | KDR 34/4885EPHB4 466/4885ERBB2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.